HUANG QINGXI (CEO, CFO, Secy., Treas.) purchased 52.8% of their position (4.29M shares) of US-CHINA BIOMEDICAL TECHNOLOGY, INC. on the open market
Open‑market purchase worth $920.21B — a major conviction buy. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 7/5/2019ACC: 0001683168-19-002124
DirectorOfficer10% Owner· CEO, CFO, Secy., Treas.
Since May 2019
+15.02M
Net shares
Net buyer
$920.21B
Total acquired
1
Open market trades
1B · 0S
2
Total transactions
15.02M acquired
Non-Derivative Transactions1
Common Stock
Indirect
Shares
+4.29M
Price / share
$214.50K
Trade value
$920.21B
% of position
52.8%
5/29/2019
8.13M→12.42M
Total
Net shares
+4.29M
Net value
$920.21B
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 5/29/2019 | P · Purchase | +4.29M | $214.50K | $920.21B | 52.8% | 8.13M | 12.42M |
| Total | +4.29M | $920.21B | ||||||
Derivative Transactions1
Warrant
Indirect
Converts to
Common Stock
10.72M shares
Shares
+10.72M
Strike price
0.05
Held after
10.72M
Exercisable
—
5/29/2019
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Warrant Indirect | Common Stock10.72M shares | 5/29/2019 | P · Purchase | +10.72M | 0.05 | — | 10.72M |